Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world’s fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries.

Recent Milestones
edit

Cephalon acquired ChemGenex Pharmaceuticals for $225M. (3/29/11)

Posted 3/29/11 at 7:49pm via com.au
Cephalon acquired Gemin X Pharmaceuticals for $525M. (3/21/11)

Posted 3/21/11 at 6:36pm via cephalon.com
Cephalon invested in SymBio Pharmaceuticals. (2/25/11)

Posted 2/25/11 at 7:42pm via symbiopharma.com
Cephalon — Cephalon Signs Option Agreement To Acquire Assets From Alba Therapeutics (2/9/11)

Posted 2/9/11 at 9:43pm via dailymarkets.com
Cephalon — Cephalon Exercises its Option to Acquire BioAssets Development Corporation (10/21/10)

Posted 10/26/10 at 6:16pm via cephalon.com
Cephalon acquired Ception Therapeutics for $250M. (2/23/10)

Posted 2/23/10 at 7:12pm via fiercebiotech.com
Went public with stock symbol NASDAQ:CEPH.

Posted 10/26/10 at 6:14pm
Cephalon added Frank Baldino, Jr. as Chairman & CEO.

Posted 2/23/10 at 7:06pm
Cephalon added J. Kevin Buchi as COO.

Posted 2/23/10 at 7:06pm